Cornerstone Pharmaceuticals is committed to providing up-to-date information about our science and progress to our many different stakeholders.

PRESS RELEASES:

June 7, 2010  Cornerstone Pharmaceuticals Appoints Timothy Sullivan Executive Vice President and Head of Corporate Development

April 21, 2010  Cornerstone's Partnership with Wake Forest University Mentioned in Forbes

April 19, 2010 Cornerstone Pharmaceuticals Partners with Wake Forest University on Clinical Trial of CP-613 for Hematologic Malignancies

March 22, 2010 Cornerstone Pharmaceuticals Enters Into a Collaboration Agreement with the U.S. National Cancer Institute

March 10, 2010 Dr. Robert Shepard Appointed Chief Medical Officer for Cornerstone Pharmaceuticals

February 8, 2010 Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First In Class Anti-Cancer Agent CPI-613

Januay 26, 2010 Cancer Metabolism Theraputics Innovator, Cornerstone
Pharmaceuticals, Announces Completion of More Than $6MM in Private Equity Financing

November 11, 2009  Cornerstone Pharmaceuticals Chosen Among Top 10 Most Interesting Oncology Projects

November 4, 2009  Leading Oncologist Dr. Robert Shepard Joins Cornerstone Pharmaceuticals as Acting Chief Medical Officer

October 5, 2009  Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to its Scientific Advisory Board

September 9, 2009   SBU Couple Develop Cancer Treatment Together

July 27, 2009 The Doctor's Channel Features Cornerstone  Pharmaceuticals

May 27, 2009  Cornerstone Pharmaceuticals Initiates Phase I/II Combination Therapy Clinical Trial of CPI-613 for Treatment of Pancreatic Cancer 

December 15, 2008  Cornerstone Pharmaceuticals Announces $6 Million Financing to Further Advance Clinical Trials in Cancer Patients 

September 24, 2008 Cornerstone Pharmaceuticals Announces Initiation of Clinical Trials of CPI-613 for the Treatment of Cancer

July 24, 2008 Cornerstone Pharmaceuticals Announces Approval to Conduct Phase I / II Clinical Trial of CPI-613 in Cancer Patients by US FDA